News

The Phase III clinical program for bapineuzumab is intended to provide safety and efficacy data to support the filing and approval. The Phase III study includes four randomized,

The double-blind, placebo-controlled trial is expected to require nine months to complete enrollment of approximately 390 amyotrophic lateral sclerosis (ALS) volunteers at 30 to 40 US and Canadian

Jazz and Solvay Pharmaceuticals are seeking marketing approval for the treatment of social anxiety disorder (SAD) and obsessive compulsive disorder (OCD).

The supplemental biological license application (sBLA) was submitted by Bristol-Myers Squibb Company to meet expected long-term demand for Orencia. Jung-Jin Seo, chairman and CEO of Celltrion, said: “Achieving

Valeant will receive from Three Rivers approximately $70.8 million in cash upon closing, and up to $20.5 million in two noncontingent payments over the following eighteen months. Under

Once the IND is approved, VGX will conduct single ascending dose (SAD) and multiple ascending dose (MAD) Phase I studies on VGX-1027 in 2008. The company is currently

This randomized, multi-center, open-label Phase II study is designed to evaluate the efficacy and safety of HGS-ETR1 in combination with carboplatin and paclitaxel as first-line therapy in the

Among the terms of the settlement is a paid-up worldwide license under the patents at issue. The amount paid by Home Diagnostics will be recorded as an expense

Under the agreement, BioSphere has agreed to make payments to DuPont of up to $500,000 based upon the achievement of specified milestones. BioSphere and DuPont will share equally